USPTO Examiner HOWARD ZACHARY C - Art Unit 1674

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19209867ANTI-CD8 ALPHA DEPLETING ANTIBODIESMay 2025September 2025Allow401YesNo
18927301PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE IIOctober 2024December 2024Allow200NoNo
18914010CHIMERIC PROTEIN COMPRISING AN ANTI-INFLUENZA VIRUS ANTIBODY MOIETY AND A MUCOADHESIVE PEPTIDE FRAGMENT FOR PREVENTING OR TREATING INFLUENZA INFECTIONSOctober 2024September 2025Allow1111YesNo
18909225METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODYOctober 2024April 2025Allow711NoNo
18830877ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTSSeptember 2024April 2025Allow711YesNo
18817109ANTI-IL-18BP ANTIBODIESAugust 2024April 2025Allow711YesNo
18773461ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPINGJuly 2024March 2025Allow811NoNo
18771877GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78July 2024November 2025Allow1611YesNo
18750581METHODS FOR TREATMENT OF PSORIASIS WITH AN ANTI-OXLDL ANTIBODYJune 2024January 2026Allow1910NoNo
18739702NUCLEIC ACIDS ENCODING MODIFIED IMMUNOGLOBULIN FC REGIONSJune 2024August 2025Allow1411NoNo
18632662ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATESApril 2024July 2025Allow1511YesNo
18615520NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAMEMarch 2024June 2025Abandon1410NoNo
18593002METHODS FOR TREATING PULMONARY DISEASE WITH A LIGAND BINDING DOMAIN OF A TGF-BETA TYPE II RECEPTORMarch 2024March 2026Allow2531NoNo
18441998METHODS OF TREATMENT OR PREVENTION OF IMMUNE RESPONSES AND INFLAMMATORY DISEASES WITH ANTAGONISTIC CD40 MONOCLONAL ANTIBODIESFebruary 2024May 2025Allow1511NoNo
18439331NME INHIBITORS AND METHODS OF USING NME INHIBITORSFebruary 2024September 2025Abandon1911NoNo
18439510METHOD OF TREATING AN IMMUNE-RELATED DISORDER OR DISEASE ASSOCIATED WITH AN ORGAN OR TISSUE TRANSPLANT WITH A COMBINATION OF AN ANTI-CD2 ANTIBODY AND A CTLA-4 CO-STIMULATION BLOCKADEFebruary 2024July 2025Abandon1721NoNo
18431294Methods of Treating Myopathies with Anti-Pro/Latent Myostatin AntibodiesFebruary 2024February 2026Allow2521NoNo
18413753AMELIORATION AND TREATMENT OF INFARCTION DAMAGE WITH A POLYPEPTIDE SEGEMENT OF BNIP3January 2024February 2025Allow1321YesNo
18396301METHODS OF TREATMENT OF CANCER WITH ANTIBODY-IL-2 ENGRAFTED PROTEINSDecember 2023December 2025Allow2321YesNo
18390569METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLSDecember 2023April 2025Abandon1601NoNo
18505590METHOD OF ASSESSING REGULATION OF AN IMMUNE RESPONSE TO AN ADMINISTERED AGENT BY MEASURING ACTIVATION OF NODOSE GANGLION NEURONSNovember 2023May 2025Allow1931NoNo
18379847METHODS OF TREATING ISCHEMIA- OR REPERFUSION-INJURY WITH AN ANTIBODY INHIBITOR OF INTEGRIN ALPHA9October 2023October 2025Abandon2421NoNo
18459465PROPERDIN BINDING PROTEIN AND USE THEREOFSeptember 2023August 2024Allow1121YesNo
18453691Antagonistic CD40 Monoclonal Antibodies and Uses ThereofAugust 2023May 2025Allow2011YesNo
18235550ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMAAugust 2023December 2025Abandon2711NoNo
18357639METHOD OF TREATING DIABETES WITH FGF21 AND GLP1 DOUBLE GENE-MODIFIED CELLJuly 2023June 2025Allow2221NoNo
18346205HETERODIMERIC RELAXIN FUSIONS AND USES THEREOFJuly 2023August 2024Allow1400NoNo
18329308NUCLEIC ACIDS ENCODING CLOSTRIDIUM HISTOLYTICUM DELTA TOXIN AND METHODS OF PRODUCING THE SAMEJune 2023May 2025Abandon2320NoNo
18200117METHODS FOR TREATMENT OF ACCELERATED ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS WITH AN ANTI-APO B100 ANTIBODYMay 2023July 2025Allow2621NoNo
18311557CMV VACCINE AND METHOD OF MAKING AND USING THE SAMEMay 2023September 2025Abandon2911NoNo
18140121METHODS OF TREATING IRON OVERLOAD WITH A BMP INHIBITORApril 2023June 2025Allow2611NoNo
18301924Anti-CD30 and Anti-CD3 Bispecific Antibodies and Methods of Immunotherapy for CD30+ MalignanciesApril 2023April 2025Allow2411NoNo
18193393TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYMarch 2023November 2024Abandon2001NoNo
18193581NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USEMarch 2023April 2025Allow2501YesNo
18125353APLNR Modulators and Uses ThereofMarch 2023December 2024Abandon2101NoNo
18163667ANTI-CD30 ANTIBODIESFebruary 2023February 2025Allow2511YesNo
18103194METHODS OF INHIBITING THE T CELL RECEPTOR BY ADMINISTERING A MONOCLONAL ANTIBODY THAT BINDS TRBV9January 2023September 2025Allow3111NoNo
18159556CELL PRIMED WITH CTGF-D4 AND INSULIN OR IGF-1 AND USE IN METHODS FOR CARDIAC TISSUE REPAIRJanuary 2023July 2025Allow2921YesNo
18156617ANTIBODY ENDOHEDRAL METALLOFULLERENE CONJUGATE AND USES THEREOFJanuary 2023June 2025Abandon2941YesNo
18012089METHOD OF TREATING AN IMMUNE-RELATED DISORDER OR DISEASE ASSOCIATED WITH AN ORGAN OR TISSUE TRANSPLANT WITH A COMBINATION OF AN ANTI-CD2 ANTIBODY AND A CTLA-4 CO-STIMULATION BLOCKADEDecember 2022February 2026Allow3811YesNo
18063981METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDINDecember 2022October 2025Allow3431YesNo
17937073METHODS OF TREATING IMMUNE-MEDIATED PULMONARY INJURY WITH AN ANTI-ILT7 ANTIBODYSeptember 2022February 2026Allow4011NoNo
17946916NUCLEIC ACIDS ENCODING SWITCH RECEPTORS USING IL-9 RECEPTOR SIGNALING DOMAINSSeptember 2022September 2024Allow2421NoNo
17933055METHODS OF TREATMENT OF ARTHRITIS AND/OR PSORIASIS WITH PHARMACEUTICAL FORMULATIONS OF ETANERCEPTSeptember 2022September 2024Allow2411NoNo
17893515LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAMEAugust 2022July 2025Allow3511NoNo
17819630Combination of Retromer Pharmacological Chaperones and Exogenous Retromer for the Treatment of Alzheimer's Disease and Other Neurodegenerative Diseases and DisordersAugust 2022January 2026Abandon4101NoNo
17819327ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF A FIBROTIC CONDITIONAugust 2022March 2026Abandon4301NoNo
17881413KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENTAugust 2022December 2024Abandon2811NoNo
17814221Method of Making Anti-Pro/Latent Myostatin AntibodiesJuly 2022December 2024Allow2921NoNo
17866188METHOD FOR REDUCING AN IMMUNE RESPONSE OF POLYPEPTIDE-FC CONJUGATEJuly 2022March 2026Abandon4421NoNo
17859130METHOD OF USING NAP-2 AND TGF-alpha TO IMPROVE CARDIAC FUNCTIONJuly 2022March 2025Allow3210YesNo
17810423C-KIT ANTIBODIES AND METHOD FOR TREATING CANCER WITH SUCHJuly 2022August 2024Allow2511NoNo
17838863T-CELL REACTIVITY PLATFORMJune 2022November 2024Abandon2911NoNo
17837943GRP78-BINDING ANTIBODIES AND USES THEREOF IN DETECTING OR NEUTRALIZING GRP78June 2022August 2024Allow2611NoNo
17836473NUCLEIC ACIDS ENCODING CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINSJune 2022September 2024Allow2811NoNo
17827100Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic InjuryMay 2022February 2025Abandon3211NoNo
17780398TEIPP PEPTIDE VARIANT AND USE AS A MEDICAMENTMay 2022September 2025Allow4011NoNo
17777335NANOVACCINE FOR HEART FAILUREMay 2022November 2025Abandon4201NoNo
17776337HUMAN HENDRA VIRUS AND NIPAH VIRUS ANTIBODIES AND METHODS OF USE THEREFORMay 2022October 2025Allow4111YesNo
17725142ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIESApril 2022October 2024Abandon3011NoNo
17718087IL-12 HETERODIMERIC FC-FUSION PROTEINSApril 2022August 2024Allow2821NoNo
17765514CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLSMarch 2022December 2025Abandon4501NoNo
17764142METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONSMarch 2022September 2025Abandon4201NoNo
17764143METHODS FOR TREATING ANEMIA OF CHRONIC DISEASEMarch 2022September 2025Abandon4201NoNo
17763925COMBINATION THERAPY WITH CGRP ANTAGONISTSMarch 2022October 2025Abandon4301NoNo
17703747ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENT IN CARDIOVASCULAR DISEASEMarch 2022November 2024Allow3221YesNo
17761088ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE THEREOFMarch 2022September 2025Abandon4201NoNo
17694295USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS TO INDICATE PREVENTION OF CARDIOVASCULAR DISEASE WITH A STATINMarch 2022May 2025Allow3820NoNo
17642837IMMUNOGENIC PEPTIDE FRAGMENTS OF METALLOPROTEASE ADAMTS-7 AND USES THEREOF IN ANTI-ATHEROSCLEROSIS AND RELATED DISEASESMarch 2022December 2025Allow4521NoNo
17666921NOVEL ANTI-TROPONIN T ANTIBODIESFebruary 2022October 2025Allow4411YesNo
17633131ANTI-HOG TCN1 MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOFFebruary 2022September 2025Allow4411YesNo
17630474METHODS OF ADMINISTERING ANTI-SIGLEC-8 ANTIBODIES AND CORTICOSTEROIDSJanuary 2022February 2026Abandon4801NoNo
17579355METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCERJanuary 2022September 2024Allow3221NoNo
17627089FUSION PROTEIN OF ANTI-ETA ANTIBODY AND TGF-BETA TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF IN METHOD OF TREATMENTJanuary 2022July 2025Allow4211NoNo
17626755ANTI-8-HYDROXY-2'-DEOXYGUANOSINE ANTIBODY OR ANTIBODY FRAGMENT THEREOF, PRODUCTION METHOD, KIT, MEASURING METHOD, AND DEVICE FOR MEASUREMENTJanuary 2022March 2025Allow3810YesNo
17626679METHODS FOR TREATING CEREBRAL VASOSPASM WITH A PD-1 AGONISTJanuary 2022January 2026Allow4911YesNo
17560022CHIMERIC RECEPTOR COMPRISING A LIGAND BINDING DOMAIN AND AN ENDODOMAIN COMPRISING A CYTOKINE RECEPTOR ENDODOMAIN AND AN INTRACELLULAR T CELL SIGNALLING DOMAINDecember 2021January 2026Allow4831YesNo
17645211NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELINDecember 2021November 2025Allow4711YesNo
17551098METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITORDecember 2021January 2026Abandon4901NoNo
17615900METHODS OF TREATING FULMINANT VIRAL HEPATITIS WITH AN IL-18 ANTAGONIST IN A PATIENT WITH AN IL-18BP VARIANTDecember 2021September 2025Allow4611NoNo
17504116ENGINEERED OSTEOCALCINS FOR TREATING SARCOPENIAOctober 2021March 2026Allow5321YesNo
17486820HUMAN APOB100 EPITOPES, METHODS AND USES FOR MODULATING INFLAMMATORY RESPONSES, AND TREATING ADVERSE CARDIOVASCULAR EVENTS, DISEASE AND ATHEROSCLEROSISSeptember 2021June 2025Allow4531YesNo
17448389METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATIONSeptember 2021May 2025Abandon4311NoNo
17405124METHODS OF USING FLT3L-Fc FUSION PROTEINS FOR THE TREATMENT OF DISEASESAugust 2021December 2024Abandon4022NoNo
17423549THERAPEUTIC NANOCONJUGATES COMPRISING STEFIN A AND USES THEREOFJuly 2021October 2025Allow5111NoNo
17359211TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTORJune 2021September 2024Allow3921NoNo
17239983METHOD FOR TREATING FIBROSIS WITH AN ANTI-GDF-15 ANTIBODYApril 2021March 2025Allow4741NoNo
17202790Methods of Treatment with Anti-PACAP AntibodiesMarch 2021August 2024Allow4121NoYes
17271767METHOD TO ASSESS CAR FUNCTIONALITYFebruary 2021December 2024Abandon4601NoNo
17271441METHODS FOR TREATING NON-SMALL LUNG CANCER AND FOR PREPARING A SAMPLEFebruary 2021August 2025Allow5321YesNo
17150457METHODS OF ADMINISTERING MESENCHYMAL STEM CELLS ACTIVATED BY CYTOKINES FOR ENHANCING IMMUNOSUPPRESSIONJanuary 2021August 2024Allow4321NoNo
17256553ANTI-CD6 ANTIBODY-GROWTH FACTOR COMPLEX FOR TREATING AUTOIMMUNE DISEASESDecember 2020March 2025Allow5021NoNo
17250259POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOFDecember 2020January 2025Abandon4911NoNo
17077433METHOD FOR TREATING PULMONARY HYPERTENSION WITH ANTIBODIES TO HUMAN RESISTINOctober 2020October 2024Allow4831YesNo
16979471NUCLEIC ACIDS ENCODING IL-13 RECEPTOR ALPHA 2 (IL13RA2) CHIMERIC ANTIGEN RECEPTOR FOR TUMOR SPECIFIC T CELL IMMUNOTHERAPYSeptember 2020July 2024Allow4611YesNo
16987237ANTI-ASGR-1 MONOCLONAL INHIBITORY ANTIBODIESAugust 2020March 2024Allow4341NoNo
16964785METHODS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN AN ORGAN WITH ANTIBODY ANTAGONISTS OF IL-33July 2020July 2024Allow4861NoNo
16964720CHIMERIC PROTEIN COMPRISING ANTI-XCR1 ANTIBODY AND MODIFIED INTERFERON ALPHA 2July 2020February 2026Allow6061YesNo
16772260Cell Comprising a Chimeric Antigen Receptor or a Transgenic T-Cell Receptor and Comprising a Chimeric TNF ReceptorJune 2020February 2025Allow5631YesNo
16753216TRANSTHYRETIN IMMUNOGLOBULIN FUSIONSApril 2020December 2024Allow5651YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOWARD, ZACHARY C.

Strategic Value of Filing an Appeal

Total Appeal Filings
26
Allowed After Appeal Filing
8
(30.8%)
Not Allowed After Appeal Filing
18
(69.2%)
Filing Benefit Percentile
46.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 30.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HOWARD, ZACHARY C - Prosecution Strategy Guide

Executive Summary

Examiner HOWARD, ZACHARY C works in Art Unit 1674 and has examined 158 patent applications in our dataset. With an allowance rate of 93.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner HOWARD, ZACHARY C's allowance rate of 93.7% places them in the 81% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HOWARD, ZACHARY C receive 2.32 office actions before reaching final disposition. This places the examiner in the 65% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HOWARD, ZACHARY C is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +9.5% benefit to allowance rate for applications examined by HOWARD, ZACHARY C. This interview benefit is in the 42% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.3% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 60.5% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 95.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 25.3% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.1% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.